Skip to main content

Table 6 Coverage of vaccine genotypes according to histological grades

From: Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination

Vaccine subgroups

Histology, n (%)

Total

≤CIN1

CIN2

CIN3

Cancer

Hierarchical modela

 6/11b

73 (3.1)

3 (1.6)

0 (0.0)

0 (0.0)

76

 16/18

990 (49.8)

106 (56.1)

176 (74.9)

13 (81.3)

1285

 31/33/45/52/58

732 (30.9)

52 (27.5)

54 (23.0)

2 (12.5)

840

 35/39/51/56/59/66/68

576 (24.3)

28 (14.8)

5 (2.1)

1 (6.3)

610

 6/11/16/18

1063 (44.8)

109 (57.7)

176 (74.9)

13 (81.3)

1361

 6/11/16/18/31/33/45/52/58

1795 (75.7)

161 (85.2)

230 (97.9)

15 (93.8)

2201

Proportional model

 6/11b

73 (3.1)

3 (1.6)

0 (0.0)

0 (0.0)

76

 16/18

904.3 (38.2)

93.5 (49.5)

172.4 (73.3)

14.6 (91.3)

1184.7

 31/33/45/52/58

691.2 (29.2)

60.6 (32.1)

57.7 (24.6)

1.4 (8.8)

811.0

 35/39/51/56/59/66/68

702.5 (29.7)

31.9 (16.9)

4.9 (2.1)

0 (0.0)

739.3

 6/11/16/18

977.3 (41.3)

96.5 (51.1)

172.4 (73.3)

14.6 (91.3)

1260.7

 6/11/16/18/31/33/45/52/58

1668.5 (70.5)

157.1 (83.1)

230.1 (97.9)

16.0 (100.0)

2071.7

Total

2371 (84.3)

189 (6.7)

235 (8.4)

16 (0.6)

2811

  1. Abbreviation: CIN cervical intraepithelial neoplasia
  2. aAccording to hierarchical ranking for CIN2+
  3. bHPV6/11 indicates only HPV6/11 infection, but excludes those coinfected with HPV6/11 and high-risk genotypes. Moreover, HPV6/11 were not included into two attribution models